
-
FGFR-2 (IIIB)
FGFR-2 (IIIB)
- 中文名称:
- FGFR-2 (IIIB)
- 英文名称:
- FGFR-2 (IIIB)
- 品牌:
- AAA Biotech
- 品牌介绍:
- AAA Biotech专注于为全球生命科学研究提供高品质的蛋白质研究工具,核心产品包括经严格验证的抗体、重组蛋白及ELISA试剂盒。
- 货号:
- AAA79332
- 规格:
- 0.1 mg|2x0.1 mg|3x0.1 mg|4x0.1 mg|5x0.1 mg
- 保存建议:
- Lyophilized samples are stable for 2 years from date of receipt when stored at -70 degree C. Reconstituted antibody can be aliquoted and stored frozen at < -20 degree C for at least for six months without detectable loss of activity.
- 货期:
- 6-8周
- 来源宿主:
- Mouse
- 反应种属:
- Human
- 应用:
- WB (Western Blot)
- 免责声明:
- *本产品仅供科研实验使用,不得用于临床诊断。*
- 其他:
克隆性:Monoclonal
同型:IgG1
克隆号:[5F48]
特异性:N/A
纯度:Protein G chromatography
形式:lyophilized; PBS
浓度:N/A
- 说明书:
Four distinct genes encoding closely related FGF receptors, FGF R1-4, are known. All four genes for FGF Rs encode proteins with an N-terminal signal peptide, three immunoglobulin (Ig) like domains, an acidbox region containing a run of acidic residues between the IgI and IgII domains, a transmembrane domain and the split tyrosinekinase domain. Multiple forms of FGF R1-3 are generated by alternative splicing of the mRNAs. A frequent splicing event involving FGF R1 and 2 results in receptors containing all three Ig domains, referred to as the alpha isoform, or only IgII and IgIII, referred to as the beta isoform. Only the alpha isoform has been identified for FGF R3 and FGF R4. Additional splicing events for FGF R13, involving the C-terminal half of the IgIII domain encoded by two mutually exclusive alternative exons, generate FGF receptors with alternative IgIII domains (IIIb and IIIc). A IIIa isoform which is a secreted FGF binding protein containing only the N-terminal half of the IgIII domain plus some intron sequences has also been reported for FGF R1. Mutations in FGF R13 have been found in patients with birth defects involving craniosynostosis. The complex patterns of expression of these receptors as well as the specificity of their interactions with the various FGF ligand family members are under permanent investigation.